Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, provides the following update on trading for the year ended 30 April 2018 ahead of its full year results to be issued in July 2018.
During the period, Kromek saw growth in sales through executing on its previously-signed agreements as well as commencing delivering on new high-value contracts won during the year. As a result, the Company expects to report revenue growth for the full year and achieve EBITDA breakeven, in-line with market expectations.
The Group’s products continue to gain traction in all its business segments from the increasing adoption of CZT-based technology and other products. The Group expects to continue to win new customers and, together with the momentum of contract wins, it expects continued growth in the new financial year.
For further information, please contact:
|Kromek Group plc|
|Arnab Basu, CEO|
Derek Bulmer, CFO
|+44 (0)1740 626 060|
|Cenkos Securities plc (Nominated Adviser and Joint Broker)|
|Max Hartley (NOMAD)|
Julian Morse (Sales)
|+44 (0)20 7397 8900|
|Cantor Fitzgerald Europe (Joint Broker)|
|+44 (0)20 7894 7000|
|Luther Pendragon Ltd (PR)|
|+44 (0)20 7618 9100|